GSK drug Jemperli met the main goal of a pivotal Phase 2 test in patients with a rare type of rectal cancer, paving the way for regulatory submissions. This antibody drug has already received a voucher to speed up its review under a new FDA pilot program.
The post GSK Eyes FDA Filing After Immunotherapy Succeeds in Key Rectal Cancer Study appeared first on MedCity News.
UCSF Health Partners with Kleiner Perkins and Doerr Capital to Launch AI Accelerator
What You Should Know Academic medical center UCSF Health, venture capital giant Kleiner Perkins, and Doerr Capital have announced the launch of UCSF Health Converge,
